— Know what they know.
Not Investment Advice

OCUL Short Interest

Ocular Therapeutix, Inc.
1W: +1.1% 1M: -12.3% 3M: -19.6% YTD: -43.1% 1Y: -41.5% 3Y: +186.0% 5Y: -41.5%
$6.72
+0.25 (+3.86%)
Pre-Market: $7.16 (+0.44, +6.55%)
Weekly Expected Move ±13.0%
$5 $6 $6 $7 $8
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 24 · $1.5B mcap · 185M float · 1.58% daily turnover · Short 55% of daily vol
Credit Risk of going bust: higher than 54% of companies Debt: 5.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 99.2%), Ocular Therapeutix, Inc. would be worth roughly what it owes.
Total debt $79.4M against a stock market value of $1.48B.
Distance to default 4.76 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $39.5M (short-term plus half of long-term), stock volatility 73.9%; Altman Z'' 0.09. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Short Volume Summary

2026-10-26
56.0%
Short Ratio
of total volume
51.4%
20-Day Avg
50.3%
50-Day Avg
▼ Falling
5-Day Trend
0.4M
Short Volume
0.8M
Total Volume

Daily Short Volume Ratio

Short Volume vs Total Volume

Exchange Breakdown

2026-10-26
ExchangeShort VolumeTotal VolumeShort %
NASDAQ 418,621 749,011 55.9%
NYSE 12,362 16,558 74.7%
BATS 80 4,064 2.0%

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms